To Explore the Surgical Outcomes and Safety of an Innovative Laparoscopic Uterine Pectopexy Technique Using Inverted T-meshes for Simultaneous Apical and Anterior Vaginal Repair.
Condition(s) studied
Investigational drug(s) / intervention(s)
Laparoscopic pectopexy: Laparoscopic pectopexy with inverted T-mesh for concomitant apical and anterior vaginal wall prolapse repair
Laparoscopic sacrocolpopexy: Laparoscopic sacrocolpopexy with double mesh for pelvic organ prolapse repair
Study summary
Patients referred for pelvic reconstructive surgery frequently present with combined anterior and apical vaginal wall prolapse. Previous studies found that anterior compartment involvement is the most common and serious defect that occurs with an apical defect. To address this, many surgeons will conduct concomitant surgeries in addition to sacrocolpopexy or pectopexy. This prospective pilot study was conducted to explore the surgical outcomes and safety of an innovative laparoscopic uterine pectopexy technique using inverted T-meshes for simultaneous apical and anterior vaginal repair.
Eligibility
Primary outcome measure(s)
- Pelvic Organ Prolapse Anatomical Outcome — 1 year post-operation
Anatomic outcomes were assessed by evaluating the pre- and post-operative prolapse stages as evaluated by the Pelvic Organ Prolapse Quantification (POP-Q) system. The plane of the hymen was defined as zero, all measures are in centimeters proximal (negative number) and distal (positive number) to the hymen. The more positive the number, the more severe the prolapse. - Rate of distress caused by pelvic floor symptoms — 1 year post-operation
These outcomes were assessed pre- and post-operation via the Pelvic Floor Distress Inventory (PFDI-20) questionnaire. Higher scores indicated greater symptom distress.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Chung Shan Medical University Hospital | Taichung | Taiwan |
More Chung Shan Medical University trials in Taiwan
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07411898 on ClinicalTrials.gov ↗ ← All trials in Taiwan